At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ACXP Acurx Pharmaceuticals, LLC*
Trading 07-22 11:54:37 EDT
1.47
-0.05
-3.29%
High1.52
Low1.47
Vol27.48K
Open1.52
D1 Closing1.52
Amplitude3.29%
Mkt Cap6.29M
Tradable Cap6.13M
Total Shares4.28M
T/O40.66K
T/O Rate0.66%
Tradable Shares4.17M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Acurx Launches Pilot Trial of Ibezapolstat in Multiply Recurrent C. Difficile Infection
Acurx Pharmaceuticals Announces Presentation of Results From Leiden University Medical Center Public-Private Partnership for Its DNA Pol Iiic Inhibitors at the Leiden Early Drug Discovery & Development (Led3) Scientific Conference
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.